-
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
•
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings…
-
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
•
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm PersonGen BioTherapeutics (Suzhou) Co., Ltd. to collaboratively develop in vivo chimeric antigen receptor (CAR)-T cell therapies utilizing CATUG’s mRNA-lipid nanoparticle (LNP) technology for global markets. As of November 2023, a total of ten CAR-T therapies…
-
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
•
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with domestic firm Carcell Biopharma, a developer of medical technology service platforms. The collaboration will focus on technical cooperation in the global development of Lipid Nanoparticle (LNP) delivered mRNA and other nucleic acid drugs, aiming to…
-
CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization
•
China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai Duoning Biotechnology Co., Ltd, with the goal of strengthening the development of its mRNA industrialization platform. The collaboration aims to enhance the production capabilities and regulatory compliance of mRNA vaccines and drugs. No financial details…
